Toggle light / dark theme

A team of researchers affiliated with several institutions in France and one in the United Arabian Emirates, has found via testing that dogs may be as effective at mass screening people for COVID-19 as publicly available tests. In their paper published on the open-access site PLOS ONE, the group describes how they tested multiple dogs sniffling human sweat samples for COVID-19 and how well they did.

Prior research has suggested that can smell it when someone near them has a disease, such as cancer. Some research has also suggested that dogs might be able to do the same with COVID-19. To find out if that is indeed the case, the researchers tested the sniffing ability of multiple dogs faced with multiple samples.

To test their ability to recognize COVID-19, multiple dogs were trained to sniff samples of human sweat and to sit down if they detected the virus. Training was done in ways similar to that done with dogs trained to sniff out explosives. Once they were tested, the dogs were taken to the Alfort School of Veterinary Medicine where cones had been set up with sweat samples in them.

Our cells perform a marvel of engineering when it comes to packing information into small spaces. Every time a cell divides, it bundles up an amazing 4 meters of DNA into 46 tiny packages, each of which is only several millionths of a meter in length. Researchers from EMBL Heidelberg and the Julius-Maximilians-Universität Würzburg have now discovered how a family of DNA motor proteins succeeds in packaging loosely arranged strands of DNA into compact individual chromosomes during cell division.

The researchers studied , a critical to the process of chromosome formation. Although this complex was discovered more than three decades ago, its mode of action remained largely unexplored. In 2018, researchers from the Häring group at EMBL Heidelberg and their collaborators showed that condensin molecules create loops of DNA, which may explain how chromosomes are formed. However, the inner workings by which the complex achieves this feat remained unknown.

“We have been working on this problem for a long time. But only now, by combining different experimental approaches, we have found an answer to this long-standing question,” said Christian Häring, former Group Leader at EMBL Heidelberg and now Professor at the Julius-Maximilians-Universität Würzburg.

A team of scientists at a company called 3DBio Therapeutics have successfully transplanted a 3D printed ear made from the patient’s own cells, The New York Times reports.

It appears to be a first in the field of tissue engineering, according to experts, and could be the harbinger of a new era of regenerative medicine.

“It’s definitely a big deal,” Carnegie Mellon biomedical engineering researcher Adam Feinberg, who was not involved in the project, told the NYT. “It shows this technology is not an ‘if’ anymore, but a ‘when.’”.

LONDON, June 1 (Reuters) — Monkeypox appears to be spreading from person to person in England, the UK Health Security Agency (UKHSA) said on Wednesday.

The usually mild viral disease, which is endemic in west and central Africa, is understood to spread through close contact. Until early May, cases rarely cropped up outside Africa and were typically linked to travel to there.

“The current outbreak is the first time that the virus has been passed from person to person in England where travel links to an endemic country have not been identified,” the agency said.

Many cancer treatments are notoriously savage on the body. Drugs often attack both healthy cells and tumor cells, causing a plethora of side effects.

Immunotherapies that help the immune system recognize and attack cancer cells are no different. Though they have prolonged the lives of countless patients, they work in only a subset of patients. One study found that fewer than 30 percent of breast cancer patients respond to one of the most common forms of immunotherapy.

But what if drugs could be engineered to attack only tumor cells and spare the rest of the body?

From banking to communication our modern, daily lives are driven by data with ongoing concerns over privacy. Now, a new EPFL paper published in Nature Computational Science argues that many promises made around privacy-preserving mechanisms will never be fulfilled and that we need to accept these inherent limits and not chase the impossible.

Data-driven innovation in the form of personalized medicine, better public services or, for example, greener and more efficient industrial production promises to bring enormous benefits for people and our planet and widespread access to data is considered essential to drive this future. Yet, aggressive data collection and analysis practices raise the alarm over societal values and fundamental rights.

As a result, how to widen access to data while safeguarding the confidentiality of sensitive, has become one of the most prevalent challenges in unleashing the potential of data-driven technologies and a new paper from EPFL’s Security and Privacy Engineering Lab (SPRING) in the School of Comupter and Communication Sciences argues that the promise that any is solvable under both good utility and privacy is akin to chasing rainbows.

Due to safety concerns, the U.S. Food and Drug Administration (FDA) has withdrawn its approval for the cancer medicine Ukoniq (umbralisib). Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL).

Updated findings from the UNITY-CLL clinical trial continued to show a possible increased risk of death in patients receiving Ukoniq. As a result, we determined the risks of treatment with Ukoniq outweigh its benefits. Based upon this determination, the drug’s manufacturer, TG Therapeutics, announced it was voluntarily withdrawing Ukoniq from the market for the approved uses in MZL and FL.

Health care professionals should stop prescribing Ukoniq and switch patients to alternative treatments. Inform patients currently taking Ukoniq of the increased risk of death seen in the clinical trial and advise them to stop taking the medicine. In limited circumstances in which a patient may be receiving benefit from Ukoniq, TG Therapeutics plans to make it available under expanded access.

Using the patient’s own cellsAn American biotech company has just announced that they have successfully transplanted a 3D printed human ear into a patient, initially reported by The New York Times. The company, Queens-based 3DBio Therapeutics, printed the ear using the patient’s own cells.


In what has been described as a world first, a U.S. company has created and transplanted a 3D-printed ear made of the patient’s own cells.